<DOC>
	<DOCNO>NCT01568034</DOCNO>
	<brief_summary>The purpose study investigate effect BIA 9-1067 levodopa pharmacokinetics administer combination immediate release levodopa/carbidopa levodopa/benserazide Parkinson 's Disease ( PD ) patient .</brief_summary>
	<brief_title>A Study Investigate Tolerability Effect Three Single-dose Regimens BIA 9-1067</brief_title>
	<detailed_description>This three-centre , double-blind , randomised , placebo-controlled , crossover study four consecutive single-dose treatment period PD patient treat immediate release 100 mg/25 mg levodopa/carbidopa 100 mg/25 mg levodopa/benserazide</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Opicapone</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Aromatic Amino Acid Decarboxylase Inhibitors</mesh_term>
	<criteria>Male female nonchildbearing potential ( reason surgery postmenopausal ) ; Aged 30 75 year , inclusive ; A diagnosis PD accord UK PDS Brain Bank diagnostic criterion ( bradykinesia least one following : muscular rigidity , rest tremor postural instability ) ; Predictable sign endofdose deterioration despite `` optimal '' levodopa/carbidopa levodopa/benserazide therapy ; Been treat stable regimen 3 8 dos standard release 100 mg/25 mg levodopa/carbidopa 100 mg/25 mg levodopa/benserazide per day within least 1 week prior randomisation ; Modified Hoehn Yahr stage le 5 offstate ; Mean duration OFF stage â‰¥ 1.5 h waking hour ( base historical information ) ; Concomitant antiParkinsonian medication ( apomorphine , entacapone tolcapone ) stable dos least 4 week prior randomisation ; Results clinical laboratory test acceptable investigator ( clinically significant wellbeing subject purpose study ) ; Able willing give write informed consent . Nonidiopathic parkinsonism ( atypical parkinsonism , symptomatic parkinsonism , Parkinsonplus syndrome ) ; Treated levodopa/carbidopa levodopa/benserazide 10:1 ratio , levodopa/carbidopa controlledrelease formulation ; Treated entacapone , tolcapone , neuroleptic , antidepressant ( except serotoninspecific reuptake inhibitor imipramines [ desipramine , imipramine , clomipramine amitriptyline ] ) , monoamine oxidase inhibitor ( except selegiline 10 mg/day oral formulation 1.25 mg/day buccal absorption formulation rasagiline 1 mg/day ) antiemetic ( except domperidone ) within 4 week prior randomisation ; Treated apomorphine within 7 day prior randomisation ; Treated investigational product within 2 month prior randomisation ( within 5 halflives , whichever long ) ; A psychiatric medical condition might place him/her increase risk interfere assessment ; Known hypersensitivity ingredient investigational product ; A history abuse alcohol , drug medication within last 2 year ; A clinically relevant ECG abnormality ; A history current evidence heart disease , include limited myocardial infarction , angina , congestive heart failure cardiac arrhythmia ; Unstable concomitant disease treat change dos medication ; A history current evidence relevant disease context study , i.e. , respect safety subject ( e.g. , hepatic renal impairment ) relate study condition ; A test positive human immunodeficiency virus ( HIV ) 1 2 antibody , hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody ( HCVAb ) ; Donated blood receive blood blood product within 6 month prior randomisation ; Pregnant , breastfeed childbearing potential ; Other condition circumstance , opinion investigator , may compromise subject 's ability comply study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Parkinson 's Disease</keyword>
	<keyword>BIA 9-1067</keyword>
</DOC>